BIONEER CORPORATION

Bioneer Showcases Tuberculosis Diagnostic Solutions at the ‘2024 Union World Conference on Lung Health’

- IRON-qPCR™ enables rapid and accurate detection of up to 40 pathogens in just 30 minutes

- RFIA Kit delivers results for multidrug-resistant tuberculosis (MDR-TB) in under 40 minutes with a single test, raising market expectations

- Strengthened global partnerships with FIND, Médecins Sans Frontières, and National Tuberculosis Control Programs

Bioneer announced on the 19th that it had participated in the 2024 Union World Conference on Lung Health, held from November 12 to 16 in Bali, Indonesia. At the conference, the company presented its innovative technologies and products, including the IRON-qPCR™ system, the RFIA Kit for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, and its recently WHO PQ-certified HIV-1 Kit.

Marking its 54th iteration, the Union World Conference is the largest international conference on lung health. It serves as a key platform for global medical professionals, public health experts, and researchers to discuss the latest advancements in the diagnosis, prevention, and treatment of lung diseases. This year’s conference highlighted key topics such as non-sputum-based tuberculosis diagnosis, pediatric tuberculosis diagnostics, and MDR/XDR tuberculosis diagnostics.

Bioneer’s IRON-qPCR™ and RFIA Kit stood out as the first solutions globally capable of simultaneously detecting MDR and XDR tuberculosis bacteria. The IRON-qPCR™ system detects up to 40 pathogens in just 30 minutes, significantly improving diagnostic speed and accuracy. Designed for syndromic diagnostic testing, this on-site molecular diagnostic system combines user convenience with high diagnostic efficiency. Unlike existing products that require two separate tests for MDR diagnosis, Bioneer’s RFIA Kit delivers results within 40 minutes with a single test, offering practical and efficient solutions for real-world application.

At the conference, Bioneer bolstered its global brand recognition and strengthened partnerships with major international health NGOs such as FIND (Foundation for Innovative New Diagnostics) and Médecins Sans Frontières. The company also expanded its network with stakeholders from National Tuberculosis Control Programs in countries such as India, the Philippines, Nigeria, and Uganda. These relationships aim to secure strategic positions in regions designated as high-priority for tuberculosis management.

A Bioneer representative stated, “By supplying tuberculosis and antibiotic resistance diagnostic products to both low- and middle-income countries with limited medical infrastructure as well as developed nations, we aim to contribute to the global eradication of diseases.” They added, “Through international health networks and collaborations, we plan to establish a solid foundation to contribute to lung health improvements worldwide.”